The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug Summit Therapeutics and Akeso shared more data for their experimental lung-cancer drug ...

Ivonescimab combo cut risk of death by 34% versus Tevimbra Akeso touts ivonescimab as a potential new standard of care for patients Global trial comparing ivonescimab to Keytruda expected to aid US ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...